{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:58:06Z","timestamp":1771930686330,"version":"3.50.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to evaluate the effectiveness of tocilizumab (TCZ) combined with short-term high-dose glucocorticoids in rapidly controlling disease activity and reducing glucocorticoid use in patients with adult-onset Still\u2019s disease (AOSD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-center retrospective study, all patients meeting the inclusion criteria were enrolled. Patients receiving short-term high-dose glucocorticoids (5 mg\/kg\/day for 3 days) with TCZ (400 mg every 4 weeks) were assigned to the TCZ group, while those receiving standard-dose glucocorticoids (1 mg\/kg\/day) without TCZ formed the non-TCZ group. Efficacy was evaluated based on laboratory data, clinical and Pouchot scores. Glucocorticoids -retention rate was estimated by the Kaplan-Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty patients (11 men, 39 women) were included (19 in the TCZ group and 31 in the non-TCZ group). The TCZ group had a higher incidence of skin rash (100% vs 58.1%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.003) and sore throat (84.2% vs 29.0%,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Over the follow-up period, inflammatory markers (CRP, ESR, SF), liver enzymes (AST, ALT), and WBC counts significantly declined in the TCZ group (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). Remission rates were higher in the TCZ group at months 1 (63.2% vs 9.7%), 3 (88.9% vs 20.0%), and 6 (83.3% vs 25.9%) (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Despite a higher initial glucocorticoid dose, no significant differences in subsequent doses were observed between groups. By 36 months, the TCZ group showed a significantly higher glucocorticoid discontinuation rate (77.0% vs 30.9%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0046). TCZ treatment was also associated with improved liver function indicators and reduced liver injury (10.5% vs 32.3%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tocilizumab combined with short-term high-dose glucocorticoids may provide rapid disease control and facilitate glucocorticoid tapering in AOSD. More prospective studies are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1732826","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:45:45Z","timestamp":1770273945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tocilizumab combined with short-term high-dose glucocorticoids for rapid disease activity control and glucocorticoid reduction in adult-onset Still\u2019s disease: a single-center retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Shi-Lei","family":"Zhong","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"Graduate School of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Ping","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"Graduate School of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Xuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"Graduate School of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Xia","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"Graduate School of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"Graduate School of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Long","family":"He","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-Bin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232112810","article-title":"Adult-onset still\u2019s disease-A complex disease, a challenging treatment","volume":"23","author":"Macovei","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000538","article-title":"Pathogenesis, disease course, and prognosis of adult-onset Still\u2019s disease: an update and review","volume":"132","author":"Wang","year":"2019","journal-title":"Chin Med J (Engl)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2018.07.018","article-title":"A comprehensive review on adult onset Still\u2019s disease","volume":"93","author":"Giacomelli","year":"2018","journal-title":"J Autoimmun"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.06.004","article-title":"Adult-onset Still\u2019s disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies","volume":"51","author":"Efthimiou","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12916-016-0738-8","article-title":"Adult-onset Still\u2019s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers","volume":"14","author":"Ruscitti","year":"2016","journal-title":"BMC Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1055\/a-2000-3446","article-title":"Update on adult-onset still\u2019s disease: diagnosis, therapy and guideline","volume":"148","author":"Vordenb\u00e4umen","year":"2023","journal-title":"Dtsch Med Wochenschr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/TCRM.S64951","article-title":"Treatment of adult-onset Still&rsquo;s disease: a review","volume":"11","author":"S\u00e8ve","year":"2014","journal-title":"TCRM"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.08.032","article-title":"Adult onset Still\u2019s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions","volume":"13","author":"Maria","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-01993-x","article-title":"Adult-onset still\u2019s disease (AOSD): advances in understanding pathophysiology, genetics and emerging treatment options","volume":"84","author":"Bindoli","year":"2024","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbi.2018.02.013","article-title":"Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters","volume":"70","author":"Del Giudice","year":"2018","journal-title":"Brain Behav Immun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152139","article-title":"Systematic review on the use of biologics in adult-onset still\u2019s disease","volume":"58","author":"Fautrel","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/art.38398","article-title":"Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still\u2019s disease: multicenter retrospective open-label study of thirty-four patients","volume":"66","author":"Ortiz-Sanju\u00e1n","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01065-6","article-title":"Recent advances and evolving concepts in Still\u2019s disease","volume":"20","author":"Ruscitti","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225854","article-title":"Efficacy and safety of therapies for Still\u2019s disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR\/PReS guidelines for the management of Still\u2019s disease","volume":"83","author":"Bindoli","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"13477","DOI":"10.1038\/s41598-017-13639-y","article-title":"A pilot study on tocilizumab for treating refractory adult-onset still\u2019s disease","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13075-019-1838-6","article-title":"Adult-onset Still\u2019s disease biological treatment strategy may depend on the phenotypic dichotomy","volume":"21","author":"Vercruysse","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222784","article-title":"Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update","volume":"82","author":"Aletaha","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/BTT.S290329","article-title":"Progress in biological therapies for adult-onset still\u2019s disease","volume":"16","author":"Galozzi","year":"2022","journal-title":"Biol Targets Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1590334","article-title":"Tocilizumab for the treatment of adult-onset Still\u2019s disease","volume":"19","author":"Casta\u00f1eda","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/OARRR.S83948","article-title":"Adult-onset Still\u2019s disease: current challenges and future prospects","volume":"8","author":"Dua","year":"2016","journal-title":"OARRR"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-06905-8","article-title":"Optimal time of starting tocilizumab in acute phase of adult-onset Still\u2019s disease and comparison of its efficacy with that of methotrexate: a case series and a review of the literature","volume":"43","author":"Suzuki","year":"2024","journal-title":"Clin Rheumatol"},{"key":"B23","article-title":"Preliminary criteria for classification of adult Still\u2019s disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199103000-00004","article-title":"Adult Still\u2019s disease: manifestations, disease course, and outcome in 62 patients","volume":"70","author":"Pouchot","year":"1991","journal-title":"Med (Baltimore)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13936","article-title":"Adult-onset still\u2019s disease and treatment results with tocilizumab","volume":"75","author":"K\u0131r","year":"2021","journal-title":"Int J Clin Pract"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2016.08.003","article-title":"Adult-onset Still\u2019s disease: Advances in the treatment","volume":"30","author":"Casta\u00f1eda","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0956-9","article-title":"Adult-onset still\u2019s disease: molecular pathophysiology and therapeutic advances","volume":"78","author":"Sfriso","year":"2018","journal-title":"Drugs"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.01.011","article-title":"Diagnosis and classification of adult Still\u2019s disease","author":"Mahroum","year":"2014","journal-title":"J Autoimmun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.881431","article-title":"Adult-onset Still\u2019s disease: A disease at the crossroad of innate immunity and autoimmunity","volume":"9","author":"Rao","year":"2022","journal-title":"Front Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac439","article-title":"AOSD endotypes based on immune cell profiles: patient stratification with hierarchical clustering analysis","volume":"62","author":"Guo","year":"2023","journal-title":"Rheumatology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1038\/s41467-018-05044-4","article-title":"Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission","volume":"9","author":"Tasaki","year":"2018","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-018-3997-1","article-title":"Activation status of peripheral blood neutrophils and the complement system in adult rheumatoid arthritis patients undergoing combined therapy with infliximab and methotrexate","volume":"38","author":"Marchi","year":"2018","journal-title":"Rheumatol Int"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04508-2","article-title":"Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis","volume":"38","author":"Elmedany","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1084558","article-title":"Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis","volume":"14","author":"Kang","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1732826\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:57:32Z","timestamp":1771927052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1732826\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2026.1732826"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1732826","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"article-number":"1732826"}}